Other Articles
April 20, 1946

ACTIVITY OF A NEW ANTIMALARIAL AGENT, CHLOROQUINE (SN 7618)Statement Approved by the Board for Coordination of Malarial Studies

Author Affiliations

New York, Chairman; Baltimore, Chairman, Panel on Biochemistry; Bethesda, Md., U. S. Public Health Service; U.S.N.R.; A. U. S.; New York, Office of Scientific Research and Development; U.S.N.; Baltimore, Chairman, Panel on Pharmacology; Urbana, III, Chairman, Panel on Synthesis; A. U. S.; U.S.N.; Bethesda, Md., U. S. Public Health Service; New York, Chairman, Panel on Clinical Testing; Washington, D. C., Executive Secretary.

JAMA. 1946;130(16):1069-1070. doi:10.1001/jama.1946.02870160015006

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


An intensive exploration of the effects of SN 7618 on animals and man has been in progress during the past two years. This has included an evaluation of the activity of this compound in avian infections, a study of the pharmacology and toxicology in animals and man and finally of its potentialities as an antimalarial against vivax and falciparum infections in man. Included in the latter category are:

  1. Extensive studies on its prophylactic activity against domestic and Southwest Pacific strains of vivax malaria, on its curative activity against sporozoite-induced infections when administered alone and in combination with other compounds, and its suppressive activity.

  2. Extensive investigations in service installations of the potentialities of this drug for use in the termination of the acute attack and in the suppression of the disease.

The pharmacology of SN 7618 has been examined in fairly extensive experiments with mice, rats, dogs, monkeys and

First Page Preview View Large
First page PDF preview
First page PDF preview